Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein–Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery-Reference-Cited by-同舟云学术

Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein–Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery

Published:2023-03-19 Issue:8 Volume:30 Page:5227-5236
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Akimoto Eigo,Kuwata Takeshi,Shitara Kohei,Kawazoe Akihito,Sakamoto Naoya,Ishii Genichiro,Ochiai Atsushi,Kinoshita Takahiro

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

https://link.springer.com/content/pdf/10.1245/s10434-023-13266-0.pdf

Reference29 articles.

1. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–9.

2. Smyth EC, Wotherspoon A, Peckitt C, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197–203.

3. Choi YY, Kim H, Shin SJ, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg. 2019;270(2):309–16.

4. Chao J, Fuchs CS, Shitara K, et al. Assessment of Pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895–902.

5. Janjigian YY, Sanchez-Vega F, Jonsson P, et al. Genetic predictors of response to systemic therapy in esophagogastric cancer. Cancer Discov. 2018;8(1):49–58.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer;Gastric Cancer;2024-05-14

2. Molecular classification and intratumoral heterogeneity of gastric adenocarcinoma;Pathology International;2024-04-23

3. Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2024-01

4. Editorial Comment on: The Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epstein–Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery;Annals of Surgical Oncology;2023-06-14